trial

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

NCTId NCT02576912
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 38 (actual)
Sponsored by Yale University
Primary completion 2019-06-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
38 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2015-02
Primary completion
2019-06-24
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Active Delta-9-THCActive Pregnenolone

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Deepak Cyril D'Souza, MDPrincipal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
38
Phase
PHASE1
Primary Completion Date
2019-06-24
Status
COMPLETED
relationships
The graph out of here
drug
Active Delta-9-THC
drug
Active Pregnenolone
drug
lead_sponsor
Yale University
company
indication
Psychotic Disorders
indication
Healthy
indication
Marijuana Abuse
indication
investigator
Deepak Cyril D'Souza, MD
person